Mark E. Dmytruk - Jan 24, 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Financial Officer
Signature
/s/ Karen Tepichin, Attorney-in-fact
Stock symbol
DNA
Transactions as of
Jan 24, 2022
Transactions value $
$0
Form type
4
Date filed
1/26/2022, 05:44 PM
Previous filing
Sep 20, 2021
Next filing
Mar 14, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Award $0 +40K $0.00 40K Jan 24, 2022 Class B Common Stock 40K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock.
F2 2. The RSUs vest as follows: 5% of the underlying shares on January 1, 2023; 12 monthly installments of 0.83% of the underlying shares thereafter; 12 monthly installments of 1.25% of the underlying shares thereafter; 24 monthly installments of 1.67% of the underlying shares thereafter; and 12 monthly installments of 2.5% of the underlying shares thereafter.

Remarks:

Chief Financial Officer